Current clinical guidelines for AML recognize three groups of cytogenetic risk—favorable, intermediate, and poor risk—through certain recurrent cytogenetic abnormalities and gene mutations, such as t(8; 21), t(15; 17), inv(16), inv(3), t(6; 9), 5q-, and NPM1, FLT3, TP53, and CEBPA mutations [3,39]. Here, TP53 is linked to acute myeloid leukemia.